---

---

Eli Lilly and Company

LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

(0.0% 1d) (-2.8% 1m) (102.7% 1y) (0.0% 2d) (-0.1% 3d) (-0.1% 7d) (Infinity% volume)
Earnings Calendar: 2024-02-06
Market Cap: $ 708,775,172,969
http://www.lilly.com
Sec Filling | Patents | 33625 employees


(US) Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Drugs

Alimta (Pemetrexed disodium)
Amyvid (Florbetapir F 18)
Bamlanivimab (Bamlanivimab)
Baqsimi (glucagon)
BASAGLAR KwikPen (Insulin glargine)
BASAGLAR Tempo Pen (Insulin glargine)
Cialis (Tadalafil)
Cymbalta (Duloxetine hydrochloride)
CYRAMZA (ramucirumab)
Effient (Prasugrel hydrochloride)
EMGALITY (galcanezumab-gnlm)
Etesevimab (Etesevimab)
Evista (Raloxifene hydrochloride)
Forteo (Teriparatide)
Gemzar (Gemcitabine hydrochloride)
Glucagon (glucagon)
Humalog (Insulin lispro)
Humalog Junior KwikPen (Insulin lispro)
Humalog KwikPen (Insulin lispro)
Humalog Mix50/50 (Insulin lispro)
Humalog Mix50/50 KwikPen (Insulin lispro)
Humalog Mix75/25 (Insulin lispro)
Humalog Mix75/25 KwikPen (Insulin lispro)
Humalog Tempo Pen (Insulin lispro)
HUMATROPE (Somatropin)
Humulin 70/30 (Insulin human)
Humulin 70/30 KwikPen (Insulin human)
Humulin N (Insulin human)
Humulin R (Insulin human)
Humulin R U-500 (Insulin human)
Humulin R U-500 KwikPen (Insulin human)
Insulin Lispro (Insulin lispro)
Insulin Lispro Junior KwikPen (Insulin lispro)
Insulin Lispro KwikPen (Insulin lispro)
Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 KwikPen (Insulin lispro)
LARTRUVO (olaratumab)
LYUMJEV (Insulin lispro-aabc)
LYUMJEV Junior KwikPen (Insulin lispro-aabc)
LYUMJEV KwikPen (Insulin lispro-aabc)
LYUMJEV Tempo Pen (Insulin lispro-aabc)
Olumiant (baricitinib)
Portrazza (necitumumab)
RETEVMO (selpercatinib)
Reyvow (lasmiditan)
Sterile Diluent (diluent)
Strattera (Atomoxetine hydrochloride)
Symbyax (Olanzapine and Fluoxetine hydrochloride)
TALTZ (ixekizumab)
TAUVID (Flortaucipir F-18)
Trulicity (Dulaglutide)
Verzenio (abemaciclib)
Zyprexa (Olanzapine)
ZYPREXA Intramuscular (Olanzapine)
ZYPREXA Relprevv (Olanzapine pamoate)
ZYPREXA Zydis (Olanzapine)

add to watch list Paper trade email alert is off

---

Press-releases

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
Published: 2024-04-17 (Crawled : 20:00) - globenewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -0.52% | O: -1.81% H: 0.0% C: 0.0%
biotech

---

Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
Published: 2024-04-17 (Crawled : 11:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| -0.09% | O: 1.03% H: 1.66% C: -1.11%
obesity tirzepatide

---

Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement
Published: 2024-04-16 (Crawled : 15:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 0.0% | O: 0.09% H: 0.0% C: 0.0%
announcement conference for financial results

---

CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors
Published: 2024-04-15 (Crawled : 20:00) - globenewswire.com
CRGX | $19.17 -1.69% -1.72% 190K |

| 0.55% | O: -1.76% H: 6.0% C: 2.35%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 0.0% | O: 0.09% H: 0.0% C: 0.0%
BDTX A | $5.295 -7.11% -7.65% 1.9M |

Health Technology

| 3.07% | O: 0.57% H: 2.86% C: 2.48%
AUTL | $4.8 -0.83% -0.83% 1.2M |

Health Technology

| -0.82% | O: 0.0% H: 2.04% C: -0.82%
therapeutics

---

Usher Syndrome Market to Exhibit Growth at a CAGR of 10.55% by 2034 | DelveInsight
Published: 2024-04-11 (Crawled : 22:00) - prnewswire.com
ALPMF | $9.594 43.47% 2.2K |

Health Technology

| -7.3% | O: -100.0% H: NaN% C: Infinity%
ALPMY | $9.46 -1.11% 500K |

Manufacturing

| -9.23% | O: -8.65% H: 3.19% C: 1.6%
JNJ | News | $145.74 0.67% 0.0% 9.3M |

Health Technology

| -3.93% | O: -1.65% H: 0.0% C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| -1.16% | O: -0.0% H: 0.52% C: -1.04%
growth market

---

Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
Published: 2024-04-11 (Crawled : 05:00) - globenewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| -0.14% | O: 1.06% H: 0.47% C: -0.03%
fda device disease test granted blood designation for alzheimer's roche

---

Blacksmith Medicines To Highlight Preclinical Oncology Data Demonstrating a Potent and Selective FEN1 Inhibitor Has Synergy with Multiple DDR Drug Classes at AACR Annual Meeting 2024
Published: 2024-04-10 (Crawled : 22:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| -0.85% | O: -0.71% H: 0.0% C: 0.0%
drug preclinical meeting

---

Global Tissue Banking Market to Exhibit Growth at a Considerable CAGR of ~6% by 2030, Assesses DelveInsight
Published: 2024-04-09 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K |

Health Technology

| -1.65% | O: -0.01% H: 0.0% C: 0.0%
TMO | News | $541.52 -1.05% 0.61% 2.1M |

Health Technology

| -7.12% | O: -2.01% H: 0.0% C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| -0.85% | O: -0.71% H: 0.0% C: 0.0%
BIO | News | $281.02 -3.38% -0.36% 370K |

Health Technology

| -13.77% | O: -2.71% H: 0.52% C: 0.24%
AVTR | $24.3 -0.33% 0.0% 4.2M |

Process Industries

| -4.87% | O: -1.7% H: 1.08% C: 0.55%
THMO | $0.613 -2.7% -2.77% 21K |

Health Technology

| -24.22% | O: 4.99% H: 2.78% C: -2.1%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -2.99% | O: -0.32% H: 0.0% C: 0.0%
global growth market

---

Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
Published: 2024-04-09 (Crawled : 20:00) - globenewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| -0.85% | O: -0.71% H: 0.0% C: 0.0%
ORIC | $9.5 -2.66% -2.74% 590K |

Health Technology

| -8.53% | O: -2.81% H: 1.54% C: -3.57%
NRIX 2 d | $14.43 2.49% 2.43% 970K |

Health Technology

| -0.04% | O: 18.35% H: 1.98% C: -5.88%
therapeutics

---

Giant-Cell Arteritis Market to Showcase Positive Growth at a CAGR of 9.3% by 2034 | DelveInsight
Published: 2024-04-08 (Crawled : 22:00) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M |

Health Technology

| -4.63% | O: -0.3% H: 0.0% C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| -3.41% | O: 0.05% H: 0.02% C: -2.62%
MOR | $18.02 -0.11% -0.11% 590K |

Health Technology

| -0.61% | O: 0.06% H: 0.22% C: 0.0%
KNSA | $16.88 -0.41% -0.41% 410K |

Health Technology

| -4.13% | O: 0.23% H: 1.58% C: 0.06%
IMAB | $1.795 -0.83% -0.84% 140K |

Health Technology

| 0.0% | O: -0.55% H: 1.39% C: 0.0%
GLPG | $28.9 -1.1% -1.11% 140K |

Health Technology

| -8.29% | O: 0.0% H: 0.39% C: -0.66%
positive growth market

---

See all

---

Your Today's Watch List

Sign in to create a watchlist

---

Gainers vs Losers

64%

36%

Top 10 Gainers

AGBA | News | $1.02 155.0% 57.94% 120M |

Finance

ZCMD | $2.86 108.76% 52.1% 2.3M |

Commercial Services

INVO | $1.555 104.6% 51.13% 5M |

Health Technology

ISPC | $0.437 105.16% 49.53% 37M |

Professional, Scientific, and T...

WLGS | News | $0.92 84.0% 45.65% 1.6M |

OST | $0.499 21.38% 45.26% 1.9M |

XPON | News | $3.1 60.62% 37.74% 17M |

TIRX | $0.7 44.39% 30.74% 58M |

BNTC | News | $6.92 44.17% 30.64% 3.5M |

Health Technology

GGE | $0.035 19.86% 29.3% 64M |

---

Last 48 Hours Insiders Buying

AXR P 2400 | $22.17 2.69% 0.0% 5.5K |

Finance

| 21:00
QCRH P 118 | $55.405 1.33% 1.31% 54K |

Finance

| 18:01
VUZI P 7500 | $1.26 3.28% 3.17% 1M |

Electronic Technology

| 18:00
RMCF | $3.61 2.27% 2.22% 18K |

Consumer Non-Durables

| 20:10

---

12 months watchlist earnings calendar

---